Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Mesothelioma, Malignant 7Unspecified Adult Solid Tumor, Protocol Specific 5Retinoblastoma 3Solid Tumors 2Sarcoma 2Mesothelioma 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Solid Tumours 1Solid Tumor 1Small Cell Lung Carcinoma 1Rhabdomyosarcoma 1Retinal Neoplasms 1Rectal Neoplasms 1Pseudomyxoma Peritonei 1Pheochromocytoma 1Peritoneal Neoplasms 1Pelvic Neoplasms 1Ovarian Neoplasms 1Optic Nerve Glioma 1Oligodendroglioma 1Neoplasm Metastasis 1Medulloblastoma 1Lung Neoplasms 1Liver Neoplasms 1Liposarcoma 1Head and Neck Neoplasms 1HER2-negative Breast Cancer 1

Interventions

pembrolizumab 4envafolimab 3Nivolumab 3Injections 2trifluridine tipiracil drug combination 1tebentafusp 1surufatinib 1sintilimab 1linifanib 1fludarabine 1cobimetinib 1TAK-981 1Ipilimumab 1Drug Therapy 1Doxorubicin 1Cyclophosphamide 1Combined Modality Therapy 1Bortezomib 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced or Metastatic Solid Tumors × Doxorubicin × Other solid neoplasm × Clear all
NCT05785754 2025-06-26

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

DynamiCure Biotechnology

Phase 1 Recruiting
320 enrolled
Other solid neoplasm

Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡